Mesoblast, Tasly plan development, regulatory approval of MPC-150-IM in China

Tasly Pharmaceutical and Mesoblast announced that the first Joint Steering Committee meeting for their cardiovascular partnership was held in Tianjin last week, and as a result Tasly plans to meet with the National Medical Products Administration of China, formerly known as the China Food and Drug Administration, in the first quarter 2019 to discuss the regulatory approval pathway for Mesoblast’s heart failure product candidate MPC-150-IM in China.
https://thefly.com/landingPageNews.php?id=2827517